4142:TPE
Adimmune Corp
17,20Â NT$
arrow_downward
−1,71%(−0,30) 1 p
30. okt, 13:30:13 GMT +8 · TWD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4142 põhistatistika genereerimine…
Ava
17,50Â NT$
Kõrge
17,60Â NT$
Madal
17,20Â NT$
Turu kapit.
7,39Â mld
Keskm. maht
1,03Â mln
Maht
964,36Â tuh
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
16,40Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Ava
17,50Â NT$
Kõrge
17,60Â NT$
Madal
17,20Â NT$
Turu kapit.
7,39Â mld
Keskm. maht
1,03Â mln
Maht
964,36Â tuh
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
16,40Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Uudised
Veebiallikatest ja uudistepartneritelt
StoneX
·
44 minuti eest
Indices Weekly Outlook: S&P 500 breaks support as wobbling AI trade weigh on stocks
CNBC
·
19 tunni eest
Anthropic's path to the Nasdaq just got a lot bumpier
MarketWatch
·
1 päeva eest
The selloff in tech stocks is shifting into overdrive
NBC News
·
1 päeva eest
Tech stocks wipe out $1 trillion in value as concerns deepen about the AI boom
Profiil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Teave üksuse Adimmune Corp kohta